Division of Abzena Ltd./PolyTherics Ltd.
Latest From PolyTherics Ltd.
Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.
Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.
Following last year’s merger of PolyTherics and Antitope, the provider of services to improve biopharmaceutical products has settled on Cambridge in the U.K. for its HQ, while a new holding structure hints at more M&A to come.
European Notebook: CHMP Opens Up A Bit; France Looks For $1B In Price Cuts; Spain Making Good On Pharma Debts
Europe's top scientific advisory panel, the CHMP, could reveal more of its thoughts on product approvals next year. French biopharma tries to stave off deep cuts in budgetary debate; Germany may consider more health reforms following recent elections; Invesco, Servier see exec changes
- Large Molecule
- Site Specific
- Drug Delivery
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Abzena Ltd.
- Senior Management
John Burt, PhD, CEO
Georg Buchner, PhD, VP, Bus. Dev.
Tim Brown, Fin. Mgr.
Antony Godwin, PhD, Dir., Science & Tech.
- Contact Info
Phone: (44) 20 7691 4927
London BioScience Innovation Centre
2 Royal College
London, NW1 0NH